

|  |                                       |
|--|---------------------------------------|
| Division: Pharmacy Policy  | Subject: Prior Authorization Criteria |
| Original Development Date:<br>Original Effective Date:<br>Revision Date: | August 6, 2021<br>March 26, 2024      |

## **OVERACTIVE BLADDER AGENTS**

**Preferred Drugs:** Toviaz<sup>®</sup> ER, Oxybutynin (tablet, syrup, extended release), Solifenacin

**Non-preferred drugs:** Detrol<sup>®</sup> (tolterodine), Detrol<sup>®</sup> LA (tolterodine ER), Darifenacin ER, Ditropan XL<sup>®</sup>, Enablex<sup>®</sup> (darifenacin), Flavoxate, Gelnique<sup>®</sup> (oxybutynin chloride 10% gel), Gemtesa<sup>®\*</sup> (vibegron), Myrbetriq<sup>®\*</sup> (mirabegron), Oxytrol<sup>®</sup> (oxybutynin transdermal system), Tolterodine, Tolterodine ER, Trospium, Trospium ER, Vesicare<sup>®</sup>, Vesicare LS<sup>™</sup>

\*Gemtesa and Myrbetriq have drug-specific criteria

**LENGTH OF AUTHORIZATION:**      Initiation of therapy: Up to 90 days  
Continuation of therapy: Up to 6 months

**INITIAL REVIEW CRITERIA:**

- Medication requested must have the FDA approved indication and patient must be within the FDA approved age limits.
- Quantity and age limits are located on the Summary of Drug Limitations at the following website: [http://www.ahca.myflorida.com/medicaid/Prescribed\\_Drug/preferred\\_drug.shtml](http://www.ahca.myflorida.com/medicaid/Prescribed_Drug/preferred_drug.shtml)
- Patient must have a diagnosis of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

**OR**

- Pediatric patient with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) (Ditropan XL<sup>®</sup>, Myrbetriq<sup>®</sup> and Vesicare LS<sup>™</sup>).
- Patient must have a history of trial and failure within the past 365 days of at least two preferred overactive bladder agents.
- Myrbetriq<sup>®</sup> can be used either alone, or in combination, with the muscarinic antagonist solifenacin succinate.

**CONTINUATION OF THERAPY:**

- Patient met initial review criteria.
- Documentation of positive clinical response.
- Dosing is appropriate as per labeling or is supported by compendia.

**DOSING AND ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>